Akshat Jain

Akshat Jain

Auto-generated profile, based on publicly available information

Akshat Jain

Loma Linda University, Redlands, California, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Blood Advances
Verified
Journal Article
Open access
SGStephanie Howe Guarino
Stephanie Howe Guarino
AJAkshat Jain
Akshat Jain
MMMohan Madisetti
Mohan Madisetti
KRKenneth Rivlin
Kenneth Rivlin
PDPayal C. Desai
Payal C. Desai
DMDeepa Manwani
Deepa Manwani
Sickle cell disease (SCD), an autosomal recessive hemoglobinopathy, affects ∼100 000 people in the United States.1 The process of transitioning from pediatric to adult SCD health care systems can be disjointed and poorly coordinated, contributing to the high morbidity and mortality seen in this population. There is no universally accepted definition of a successful SCD care transition, nor are there existing standards and recommendations for SCD clinicians. National Alliance of Sickle Cell Centers (NASCC) uses a described modified Delphi process to reach consensus among its members, through which we defined standards and recommendations for transitioning care from pediatric to adult care health systems, including the definition of successful transfer and integration into adult care, as well as the essential health data elements needed for a standardized electronic health record transition note to facilitate clinician communication. NASCC members from pediatric, adult, and life span SCD centers evaluated standards and recommendations for successful transfer and integration of care, as well as pediatric and adult transition program operating practices. Consensus was achieved for 4 standards and 14 recommendations for transition from pediatric to adult care in SCD in the areas of transition policies, documents, tracking, definitions of successful transfer and transition of care, and initial visit responsibilities. This initiative defines 2 key elements of successful transition, which will allow for the study of interventions to improve outcomes. Importantly, these materials now provide the needed framework and quantifiable metrics for clinicians to evaluate their transition programs for quality improvement.

17 January 2025 in Journal of Sickle Cell Disease
Verified
Journal Article
Open access
AJAkshat Jain
Akshat Jain
LRLisa Roberts
Lisa Roberts
SSSafiye Sahin
Safiye Sahin
Objectives: The aim of this study is to assess the global knowledge, awareness, and access to care for individuals with sickle cell disease (SCD) focusing on disparities between low-middle and high income countries. Methods: A cross-sectional survey with 127 participants was conducted in 11 countries across multiple global regions between February and September in 2024. Data were collected through surveys including questions from various scales such as Short Form Health Survey-36 (SF-36). Data were analyzed through descriptive statistics and chi-square tests, using SPSS (version 29) with a significance level of P < .05. Results: Findings show significant differences in early diagnosis, with 81.8% of high income country participants diagnosed at birth, compared to 53.1% in low-middle income countries (P < .001). While 87.3% of all participants understood SCD as a genetic disorder, awareness of stem cell transplantation was higher in high income countries (95.2%) than in low-middle income countries (63.6%) (P = .014). Access to mental health services was also notably higher in high income countries; only 12.1% of participants in low-middle income countries had access to mental health services, compared to 47.4% in high income countries (P = .003). Conclusion: The study underscores the urgent need for comprehensive healthcare strategies, including expanded newborn screening, improved financial support, and enhanced mental health services, particularly in low-middle income countries.

2 June 2026 in Blood
Verified
Journal Article
Closed access
EEErica B Esrick
Erica B Esrick
LLLeslie Lehmann
Leslie Lehmann
AFAmy Federico
Amy Federico
HVHelene Vincon
Helene Vincon
BLBoya Liu
Boya Liu
DWDavid A Williams
David A Williams
Sickle cell disease (SCD) is characterized by chronic hemolysis, painful vaso-occlusive episodes (VOE) and end organ damage. High levels of fetal hemoglobin (HbF) attenuate the disease phenotype. We used a lentivirus vector (LVV) expressing an shRNA embedded in a microRNA (shmiR) targeting BCL11A in erythrocytes to induce HbF in a first-in-human pilot study in SCD. The purpose of the study was to assess hematopoietic stem/progenitor cells (HSPCs) collection, transduction parameters, safety, HbF induction and durability. Eleven eligible patients with SCD had HSC collection. Plerixafor-mobilized peripheral blood HSCs required for manufacturing were obtained in one mobilization cycle for 10/11 subjects and 11/11 patient products were successfully manufactured with a median time to release of product of 39 days. Ten patients were infused with autologous HSCs transduced with the shmiR vector. Engraftment occurred in all 10 patients. With a median follow-up of 58 months (range: 35-82) after infusion, no adverse events attributed to the gene vector have occurred. Transduction efficiency was 93.1%. One patient demonstrated low engraftment of transduced cells and had suboptimal HbF induction. In the remaining 9 patients, at 2 years post-treatment peripheral blood demonstrated 71% F cells with 11.9 pg HbF/F cells, both stable in 9 patients with ≥48 months follow-up. All patients who had VOEs prior to gene therapy demonstrated sustained mitigation of pain events. These data demonstrate excellent manufacturing efficiency and safety, with efficacy of targeting BCL11A using a shmiR LVV, and long-term durability of the shmiR vector, leading to a pivotal multi-site phase 2 trial currently underway (NCT05353647).

12 August 2026 in Blood Global Hematology
Verified
Journal Article
Open access
AJAkshat Jain
Akshat Jain

13 October 2026 in Blood Vessels, Thrombosis & Hemostasis
Verified
Journal Article
Open access
AJAkshat Jain
Akshat Jain
CLCindy Leissinger
Cindy Leissinger
VVVladimir Vdovin
Vladimir Vdovin
PZPavel Zharkov
Pavel Zharkov
LDLeonid Dubey
Leonid Dubey
RSRobert F. Sidonio
Robert F. Sidonio

18 May 2020
Verified
Preprint
Open access
MMMary Meyer
Mary Meyer
AJAkshat Jain
Akshat Jain
Approximately 13 patients with hemophilia A or B have been reported to be diagnosed with acute leukemia in childhood [1, 2]. This rarity appeared again in a 13 year old male with severe hemophilia with inhibitors who presented with worsening bone pain, weight loss, and leukocytosis. Coexistence of these life-threatening disorders, hemophilia and acute leukemia, pose practical challenges in providing standard care as the former has a propensity of bleeding and the latter requires intensive treatment with systemic and intrathecal chemotherapy. Our discussion aims at highlighting critical care strategies in management of severe hemophilia and hematologic malignancies.